What one share of SpyGlass Pharma holds
We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.
SpyGlass Pharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.91 |
|---|---|
| Capex (buildings and equipment) | $0.22 |
| Free cash flow | −$3.47 |
| Cash and investments | $6.67 |
| Book value | $6.95 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$16.31 | $1.11 | −$13.43 | — | −$27.53 |
| 2025 | — | −$17.98 | $0.36 | −$15.11 | — | −$44.85 |
Common questions about SpyGlass Pharma
How much does one share of SpyGlass Pharma earn?
Over the last 12 months, SpyGlass Pharma lost $3.91 for each share.
Does SpyGlass Pharma pay a dividend?
SpyGlass Pharma didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is SpyGlass Pharma’s book value per share?
SpyGlass Pharma’s book value is $6.95 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of SpyGlass Pharma have?
Each share of SpyGlass Pharma has $6.67 of cash and investments, as of June 30, 2026.
What is SpyGlass Pharma’s free cash flow per share?
−$3.47 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.